Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Tissue Regenix produces impressive results in leg ulcer trial

All twenty patients treated with Tissue Regenix’s dCELL Dermis saw a significant reduction in their wounds while nine were completely healed.
Tissue Regenix produces impressive results in leg ulcer trial

Tissue Regenix’s (LON:TRX) replacement skin has continued to generate impressive results in a Manchester-based trial to treat chronic leg ulcers. 

All twenty trial patients treated with Tissue Regenix’s dCELL Dermis saw a significant reduction in their wounds while nine were completely healed.

Tissue Regenix's dCELL Dermis is human skin that has been treated with its dCELLprocess, a patented technology that involves taking human or animal tissue and “washing” it so that it can be used again to replace worn out or diseased body parts without the risk of rejection.

The ongoing trial is being carried out in conjunction with the NHS Blood and Transplant division and is focused on people who have suffered with chronic ulcers for more than four years.

Tissue said as well as nine patients being healed, the surface area of all of the patient’s ulcers had halved in size, with volume also reduced significantly. The results were after six weeks.

The study also showed that the new skin could applied in 30- 40 minutes without hospital admission - in out-patient clinics and potentially GP surgeries - and can be tailored to fit a wound.  

Dr Ardeshir Bayat, the trial's principal investigator at the University Hospital of South Manchester said: "These are encouraging interim results. The decellularised matrix appears to be providing a 'kick start' to heal these difficult wounds.  

"Chronic wounds of the lower leg are a clinical challenge and their on-going treatment costs the NHS in excess of £400m per annum. Therefore a novel solution that can both reduce these costs and simultaneously offer a more effective treatment strategy has been long overdue."

Antony Odell, Tissue Regenix’s managing director added: "People who suffer with chronic leg ulcers often do so for many years. Traditional treatments using compression bandages are not effective in many cases and require regular hospital visits and the associated disruption to their daily lives. 

"However, early results from this trial indicate that our dCELLtechnology could play an important role in treating patients who endure this painful condition, as well as deliver cost effective solution to the NHS by negating the need for regular treatment over a prolonged period."

Odell added that the company expects to publish the results of a pre-clinical knee cartilage replacement trial before the end of the year, while a number of different products including the ligament and cardiac patch are due to enter preclinical studies.

Tissue Regenix had also been selected as one of only twenty UK healthcare companies to attend the Future Healthcare Mission to showcase the best in UK medical and healthcare science and technology to US investors and business partners, he said. 

“We believe Tissue Regenix is an excellent example of a British company with world-beating technology, which is based on research conducted in UK universities and pioneered through patient treatment in the NHS."

Tissue had net cash at the end of July of £26.1 mln. The company raised £25m through a share placing in December.

Losses in the half year rose to £1.87 mln from £1.34 mln reflecting the heavy product development currently underway, it said.

 

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use